Aeterna Zentaris CEO David J. Mazzo And Chief Business Officer Ellen McDonald: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Execs discuss how their BPH treatment will take on products such as Pfizer’s Detrol and GlaxoSmithKline’s Avodart, as well as how their development strategy differs from other biopharmas.
You may also be interested in...
Aeterna Zentaris Projects 2010 Filing, 2011 Launch For BPH Candidate
Canadian biotech accelerates cetrorelix development while boosting cash-burn guidance.
Aeterna Zentaris Projects 2010 Filing, 2011 Launch For BPH Candidate
Canadian biotech accelerates cetrorelix development while boosting cash-burn guidance.
Aeterna Shifts Directions Again; CEO And Senior VP Depart
Interim CEO says Canadian biotech will continue development of prostate cancer drug and seek to divest additional non-core assets.